Kayne Anderson Rudnick Investment Management LLC Travere Therapeutics, Inc. Transaction History

Kayne Anderson Rudnick Investment Management LLC

$43.7 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	SELL	$20.94 - $30.01 $1,507 - $2,160	-72 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $1,699 - $2,203	72 New	72 $2,000

Others Institutions Holding TVTX

# of Institutions

193

Shares Held

84.6M

Call Options Held

776K

Put Options Held

900K

Armistice Capital, LLC New York, NY

7.65M
Shares

$143 Million
1.78% of portfolio
Black Rock Inc. New York, NY

7.64M
Shares

$143 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.9M
Shares

$129 Million
0.0% of portfolio
Rock Springs Capital Management LP Baltimore, MD

4.68M
Shares

$87.8 Million
2.23% of portfolio
Woodline Partners LP San Francisco, CA

4.34M
Shares

$81.4 Million
0.55% of portfolio

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.2B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kayne Anderson Rudnick Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kayne Anderson Rudnick Investment Management LLC with notifications on news.

Account